Crohn’s disease and ulcerative colitis are collectively known as inflammatory bowel disease. Both conditions affect the bowel, but in slightly different ways.
In three recent studies, researchers evaluated the efficacy and safety of risankizumab for patients with moderately to severely active Crohn’s disease, and of upadacitinib for patients with moderately to severely active ulcerative colitis. The results showed that both therapies were efficacious and well tolerated as induction and maintenance therapy in patients with inflammatory bowel disease. The results of these studies offer new therapeutic options for a broad range of patients by meeting endpoints that might change the future course of these diseases.
If you would like to read more about these studies, you can find them on the profile of Prof. D'Haens at the scopus website.
